Skip to main content

Table 2 Univariate Cox regression analysis of KLK12 mRNA expression in relation to patients’ outcome in triple-negative breast cancer

From: Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients

Clinical parameters OS DFS
No.a HR (95% CI)b p No.a HR (95% CI)b p
Age    <  0.001    0.001
 ≤ 60 years 67 1   67 1  
 > 60 years 58 2.96 (1.63–5.36)   56 2.45 (1.42–4.23)  
Lymph node status    0.055    0.118
 N0 70 1   69 1  
 N1/N2/N3 55 1.74 (0.99–3.07)   54 1.53 (0.90–2.59)  
Tumor size    0.117    0.204
 ≤ 20 mm 33 1   33 1  
 > 20 mm 91 1.83 (0.86–3.92)   89 1.54 (0.79–2.98)  
Histological grade    0.915    0.600
 II 21 1   21 1  
 III 104 1.04 (0.49–2.23)   102 1.22 (0.58–2.59)  
KLK12 mRNAc    0.037    0.010
 Negative 61 1   59 1  
 Positive 54 1.91 (1.04–3.50)   54 2.12 (1.19–3.78)  
KLK12 mRNA posd    0.047    0.051
 Low 16 1   16 1  
 High 38 2.98 (1.02–8.74)   38 2.64 (1.00–6.96)  
  1. Significant p-values (p ≤ 0.05) are indicated in bold, trends towards significance (p ≤ 0.06) in italics
  2. Due to missing values, numbers do not always add up to n = 125 (OS) and n = 123 (DFS), when the whole cohort is analyzed
  3. a Number of patients
  4. bHR Hazard ratio (CI Confidence interval) of univariate Cox regression analysis
  5. c Dichotomized into positive and negative expression
  6. d Positive KLK12 mRNA values were dichotomized into low and high expression by the 30th percentile